Expert Analysis

First-line Therapy and Switch Strategies

Source: CCO Independent Conference Coverage of the 2005 International AIDS Society Conference on HIV Pathogenesis and Treatment*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

First-line Therapy and Switch Strategies

Program Director: John P. Phair, MD

Faculty:

Joel E. Gallant, MD, MPH
W. David Hardy, MD
Mauro Schechter, MD, PhD

CME CREDIT INFORMATION

Release Date: 10/07/05

Expiration Date: 10/06/06

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.7 Nursing CE credits

Pharmacists: 1.4 contact hours (0.14 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss treatment outcomes observed in patients initiating antiretroviral therapy in resource-limited countries.
Explain the results of trials investigating outcomes in patients modifying antiretroviral therapy to manage toxicity.
Describe recent data on immunologic parameters for initiation of antiretroviral therapy.
Recount key efficacy and safety data from recent clinical trials comparing first-line antiretroviral regimens.

Topics covered include:

When to Start
GS 934: Tenofovir + Emtricitabine vs Zidovudine/Lamivudine for HAART Initiation
Zidovudine/Lamivudine Plus Tenofovir
Response to Therapy in Brazil
GS 903e Extension Study
OK Study: Maintenance With Lopinavir/Ritonavir Monotherapy
SWAN Study: Switch to Atazanavir
Immunologic Responses to Therapy

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.